Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)
April 10, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting
April 09, 2013 15:00 ET
|
Arbutus Biopharma Corporation
TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving Doses in Effective Range
Tekmira to Initiate a Phase II Clinical Trial in Gastrointestinal Carcinoid (Neuroendocrine)...
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results
March 27, 2013 16:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Year-End 2012 Financial Results
March 20, 2013 16:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., March 20, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will...
Tekmira Outlines Key 2013 Product Development and Corporate Milestones
February 12, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference
February 06, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR
February 04, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery
January 31, 2013 16:05 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Acquires Worldwide License to Novel RNAi Technology
November 29, 2012 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 29, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results
November 13, 2012 06:30 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...